635698-56-5

Basic information

• Product Name: TERT-BUTYL 2,4-DICHLORO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDINE-6(5H)-CARBOXYLATE
• Synonyms: 2,4-Dichloro-,5,6,7,8-tetrahydro-6-Boc-Pyrido[4,3-d]pyrimidine;Pyrido[4.3-d]pyriMidine-6(5H)-carboxylicacid. 2.4-dichloro-7.8-d;6-Boc-2,4-Dichloro-5,6,7,...;6-Boc-2,4-Dichloro-5,6,7,8-tetrahydropyrido[4,3-d]pyriMidine;tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[4,3-d]pyriMidine-6-carboxylate;6-Boc-2,4-Cl2-5,7,8-H3-pyrido[4,3-d]pyrimidine;2,4-Dichloro-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid tert-butyl ester;TERT-BUTYL 2,4-DICHLORO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDINE-6(5H)-CARBOXYLATE
• CAS NO: 635698-56-5
• Molecular Formula: C₁₂H₁₅Cl₂N₃O₂
• Molecular Weight: 304.17
• EINECS: 1533716-785-6
• Product Categories: CHIRAL CHEMICALS;pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 635698-56-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 423.1 °C at 760 mmHg
• Flash Point: 209.7 °C
• Appearance: /
• Density: 1.352g/cm³
• Vapor Pressure: 2.3E-07mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.98±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL 2,4-DICHLORO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDINE-6(5H)-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 2,4-DICHLORO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDINE-6(5H)-CARBOXYLATE(635698-56-5)
• EPA Substance Registry System: TERT-BUTYL 2,4-DICHLORO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDINE-6(5H)-CARBOXYLATE(635698-56-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 635698-56-5(Hazardous Substances Data)

Usage

General Description

Tert-butyl 2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate is a chemical compound with a complex molecular structure. It is a derivative of 2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidine and is commonly used in the pharmaceutical industry for the synthesis of various drugs. TERT-BUTYL 2,4-DICHLORO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDINE-6(5H)-CARBOXYLATE is known for its potential medicinal properties and is currently being studied for its potential use in the development of new pharmaceuticals. Its unique molecular structure and properties make it an important compound in the field of medicinal chemistry.

InChI:InChI=1/C12H15Cl2N3O2/c1-12(2,3)19-11(18)17-5-4-8-7(6-17)9(13)16-10(14)15-8/h4-6H2,1-3H3

Upstream product

• 41276-30-6 C₉H₁₄O₃NC₆H₅ 

Downstream Products

• 635699-26-2 tert-butyl 2-chloro-4-(2,4-dichlorobenzylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carboxylate 
• 1207358-19-7 C₂₄H₂₈N₈O₂ 
• 1207358-03-9 C₂₀H₂₆N₆O₂ 
• 1207358-49-3 C₂₆H₃₆N₆O₄ 
• 1207358-51-7 C₂₁H₂₈N₆O₂ 
• 1542705-58-7 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[4,3-d]-pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide 

Relevant articles and documents

Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)

The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin-proteasome system (UPS) mediated protein degradation, endoplasmic reticulum-associated degradation (ERAD), and autophagy. Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-5083. Treatment of tumor cells with 71 leads to significant accumulation of markers associated with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell death. In tumor bearing mice, oral administration of 71 causes rapid accumulation of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to sustained antitumor activity in in vivo xenograft models of both solid and hematological tumors. 71 has been taken into phase 1 clinical trials in patients with multiple myeloma and solid tumors.